Eg5 Inhibitor
Showing 1 - 25 of >10,000
Advanced MDS, Acute Myeloid Leukemia Trial in Atlanta, Houston (ARRY-520, KSP(Eg5) inhibitor; intravenous)
Completed
- Advanced MDS
- Acute Myeloid Leukemia
- ARRY-520, KSP(Eg5) inhibitor; intravenous
-
Atlanta, Georgia
- +1 more
Feb 4, 2021
Advanced Solid Tumors Trial in Baltimore, Detroit (ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony
Completed
- Advanced Solid Tumors
- ARRY-520, KSP(Eg5) inhibitor; intravenous
- Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
-
Baltimore, Maryland
- +1 more
Sep 24, 2020
MDD Trial in Shibin Al Kawm (Sildenafil Citrate, Placebo oral tablet)
Recruiting
- Major Depressive Disorder
- Sildenafil Citrate
- Placebo oral tablet
-
Shibīn Al Kawm, EgyptFaculty of Medicine
Jan 16, 2023
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD Trial
Not yet recruiting
- Neuromyelitis Optica Spectrum Disorder
- +2 more
- (no location specified)
Jul 21, 2023
Breast Cancer Trial (GSK3326595)
Completed
- Breast Cancer
-
London, Ontario, CanadaSt. Joseph's Health Care London
Oct 24, 2022
Advanced Multiple Myeloma Trial in United States (Carfilzomib, proteasome inhibitor; intravenous, Filanesib, KSP(Eg5) inhibitor;
Completed
- Advanced Multiple Myeloma
- Carfilzomib, proteasome inhibitor; intravenous
- +3 more
-
Hot Springs, Arkansas
- +21 more
Sep 14, 2020
Phosphodiesterase Type 5 Inhibitor to Improve Anabolic
Not yet recruiting
- Sarcopenia
- Tadalafil 5mg
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Jul 25, 2022
Advanced Solid Tumours That Are MTAP Deficient Trial in Spain, United States (AZD3470)
Not yet recruiting
- Advanced Solid Tumours That Are MTAP Deficient
-
New Haven, Connecticut
- +3 more
Nov 8, 2023
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- BCX9930
- +2 more
-
Paris, France
- +6 more
Dec 15, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)
Recruiting
- Breast Cancer
- ER Positive Breast Cancer
- Letrozole 2.5mg
-
Lebanon, New Hampshire
- +1 more
Dec 19, 2022
Congenital Diaphragmatic Hernia, Pulmonary Hypertension Trial in Salt Lake City (Sildenafil Oral Suspension, Placebo)
Not yet recruiting
- Congenital Diaphragmatic Hernia
- Pulmonary Hypertension
- Sildenafil Oral Suspension
- Placebo
-
Salt Lake City, UtahPrimary Children's Hospital
Jan 27, 2022
Locally Advanced Colon Cancer Trial (Serplulimab, short-term radiotherapy, Oxaliplatin)
Not yet recruiting
- Locally Advanced Colon Cancer
- Serplulimab
- +3 more
- (no location specified)
Feb 16, 2023
Erectile Dysfunction Trial in Saint Petersburg (PDE5 inhibitor (tadalafil) and BTL-6000 fSWT, PDE5 inhibitor (tadalafil))
Recruiting
- Erectile Dysfunction
- PDE5 inhibitor (tadalafil) and BTL-6000 fSWT
- PDE5 inhibitor (tadalafil)
-
Saint Petersburg, Russian FederationSBPSU
Apr 10, 2023
Jaw, Edentulous Trial in Germany, Switzerland, United Kingdom (OmniTaper EV implants)
Recruiting
- Jaw, Edentulous
- OmniTaper EV implants
-
Ludwigshafen, Germany
- +5 more
Jan 18, 2023
Lung Cancer Trial (TILT-123, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- TILT-123
- Pembrolizumab
- (no location specified)
Nov 5, 2023
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +5 more
- (no location specified)
Apr 8, 2023
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in
Recruiting
- Malignant Pleural Mesothelioma, Advanced
- Oncolytic Adenovirus H101
- Programmed death receptor-1 inhibitor
-
Tianjin, Tianjin, ChinaTianjin Medical Unversity Second Hospital
Sep 2, 2023
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)
Completed
- Chronic Lymphocytic Leukemia
-
Louisville, Kentucky
- +66 more
Nov 9, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Chemotherapy Combined With Immunotherapy or Chemotherapy
Completed
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 9, 2022